Argent BioPharma
Argent BioPharma · page 2
- Markets & Stocks
Ananda Stock Returns to AJ Bell Platform Following Backlash, Kanabo Stock Jumps 30% on Financial Results, & Argent Seeks to Shift Listing
Ananda Developments [stock_market_widget type=”chart” template=”line” assets=”ANA.AQ” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Ananda Developments’ CEO has seemingly forced the hand of one of the UK’s most popular investment service providers, AJ Bell, after it decided to cut a raft of smaller-cap companies from its online trading platform.
- Markets & Stocks
Argent BioPharma Sees 74% Sales Decline, Cantourage Enjoys 62% Sales Increase, & Organigram Progresses With BAT Investment
Argent BioPharma [stock_market_widget type=”chart” template=”line” assets=”RGT.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Argent BioPharma (formerly MGC Pharmaceuticals) has released its latest preliminary financial figures for the year to June 30, 2024, revealing a sharp drop in revenues but a reigning in of net losses compared to the previous year.
- Markets & Stocks
Synbiotic Hails Sales Growth Post-CanG, Stenocare Halves Sales Forecast for 2024, & Argent Bio. Delists From ASX
Synbiotic [stock_market_widget type=”chart” template=”line” assets=”SBX.F” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] German cannabis group Synbiotic published an update on its eclectic portfolio of businesses this week, seeing sales rise across the board following the passage of CanG.
- Markets & Stocks
IMC Stock Jumps Over 60%, Akanda Announces New Strategic Plan, & MGC Becomes Argent BioPharma
IM Cannabis [stock_market_widget type=”chart” template=”line” assets=”IMCC” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] IM Cannabis has seen its share price skyrocket by over 65% this week, despite reporting a 10% decline in revenues and over $10m in net losses in 2023.
- Markets & Stocks
MGC Pharma to Rebrand to Argent BioPharma, OCT Explores Capital Reorganisation, & Cannabis Poland’s Stock Skyrockets
MGC Pharmaceuticals / Argent BioPharma [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”MXC.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] MGC Pharmaceuticals has become the latest UK-listed cannabis company to opt for a rebrand in 2024, as businesses increasingly try to diversify and distance themselves from the difficulties experienced across the cannabis sector over the last year…
